Skip to main content

Table 3 Cox regression multivariate analysis of variables for overall survival in AML patients

From: Comprehensive analysis of ID genes reveals the clinical and prognostic value of ID3 expression in acute myeloid leukemia using bioinformatics identification and experimental validation

Variables

Total AML

CN-AML

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

Age

1.040 (1.025–1.055)

< 0.001

1.028 (1.012–1.044)

< 0.001

1.023 (1.005–1.042)

0.014

1.012 (0.991–1.034)

0.272

WBC

1.005 (1.001–1.008)

0.018

1.007 (1.003–1.011)

0.002

1.005 (1.000-1.010)

0.032

1.003 (0.998–1.009)

0.223

Molecular risks

1.921 (1.487–2.481)

< 0.001

2.184 (1.609–2.963)

< 0.001

1.817 (0.760–4.344)

0.179

1.552 (0.573–4.201)

0.387

Treatment regimen

0.519 (0.355–0.761)

0.001

0.426 (0.275–0.661)

< 0.001

0.525 (0.306–0.902)

0.020

0.424 (0.240–0.746)

0.003

FLT3 mutationa

1.325 (0.885–1.984)

0.171

1.642 (1.059–2.546)

0.027

1.418 (0.818–2.458)

0.214

-

-

NPM1 mutation

1.155 (0.770–1.732)

0.486

-

-

1.059 (0.620–1.809)

0.833

-

-

TP53 mutation

4.100 (2.291–7.339)

< 0.001

2.513 (1.288–4.903)

0.007

2.614 (0.354–19.301)

0.346

-

-

CEBPA mutationb

0.928 (0.470–1.834)

0.831

-

-

1.011 (0.432–2.365)

0.980

-

-

ASXL1 mutation

2.365 (0.749–7.473)

0.142

3.634 (1.091–12.102)

0.036

10.795 (1.328–87.751)

0.026

19.441 (2.200-171.761)

0.008

RUNX1 mutation

1.069 (0.761–1.051)

0.702

-

-

1.271 (0.502–3.214)

0.613

-

-

ID1 expression

1.433 (0.991–2.073)

0.056

1.301 (0.853–1.985)

0.222

1.074 (0.627–1.840)

0.794

-

-

ID2 expression

1.530 (1.056–2.216)

0.025

1.050 (0.690–1.598)

0.819

1.224 (0.717–2.088)

0.459

-

-

ID3 expression

0.741 (0.512–1.072)

0.112

0.712 (0.465–1.090)

0.118

0.516 (0.284–0.939)

0.030

0.502 (0.278–0.906)

0.022

ID4 expression

0.823 (0.569–1.189)

0.300

-

-

0.555 (0.319–0.964)

0.037

0.492 (0.263–0.922)

0.027

  1. Variables including age (continuous variables), WBC (continuous variables), treatment regimen (with transplantation vs. without transplantation), molecular risks (good, intermediate, poor and unknown; classified by the 2017 European LeukemiaNet classification), FLT3/NPM1/TP53 mutation (wild type vs. mutant) and ID1/2/3/4 expression (low vs. high). Multivariate analysis includes variables with P < 0.200 in univariate analysis
  2. AML Acute myeloid leukemia, CN-AML Cytogenetically normal AML, HR Hazard ratio, CI Confidence interval, WBC White blood cells
  3. a FLT3 mutation indicates both FLT3-ITD (high and low ratios) and FLT3-TKD mutations
  4. b CEBPA mutation indicates both mono- and bi-allelic CEBPA mutation
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us